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ABSTRACT 
An efficient methodology for the preparation of the -tetrasubstituted proline analogue (S,S,S)-2-
methyloctahydroindole-2-carboxylic acid, (S,S,S)-( Me)Oic, and its enantiomer, (R,R,R)-
( Me)Oic, has been developed. Starting from easily available substrates and through simple 
transformations, a racemic precursor has been synthesized in excellent yield and further subjected 
to HPLC resolution using a cellulose-derived chiral stationary phase. Specifically, a semi-
preparative (250  20 mm ID) Chiralpak
®
 IC column has allowed the efficient resolution of more 
than 4 grams of racemate using a mixture of n-hexane/tert-butyl methyl ether/2-propanol as the 
eluent. Multigram quantities of the target amino acids have been isolated in enantiomerically 
pure form and suitably protected for incorporation into peptides.  
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INTRODUCTION 
Peptides are mediators of key biological functions in our organism and, thereby, provide a great 
opportunity for therapeutic applications. However, the use of natural peptides as drugs is strongly 
limited by their rapid metabolism, low bioavailability and poor receptor subtype selectivity.
1
 
Therefore, much effort is being devoted to endow peptides with enhanced therapeutic properties. 
In this context, the incorporation of constrained -amino acids into peptides constitutes a very 
useful strategy to reduce their flexibility and retard enzymatic degradation.
1,2
 Moreover, restricted 
-amino acids stabilize particular conformational features, which may lead to improvements in 
the biological potency if the bioactive conformation is tethered.
1,2
 
In particular, -methylation of -amino acids is an efficient way to produce surrogates with 
defined conformational preferences.
3
 Indeed, the incorporation of -methyl amino acids into 
peptides has shown to reduce their conformational freedom and to prevent the hydrolytic 
cleavage of neighboring peptide bonds.
1,2,4
 Among them, -methylproline
5
 [( Me)Pro, Fig. 1)] 
has frequently been used as a replacement for proline to control the secondary structure, and 
hence, the biological behavior of peptides.
6–8
 The great number of patents dealing with bioactive 
peptides containing ( Me)Pro provides evidence for the enormous value of this amino acid (in 
general, of -methylated amino acids) in the development of therapeutic agents. 
<Figure 1> 
Octahydroindole-2-carboxylic acid (Oic, Fig. 1) is a proline analogue containing a fused 
cyclohexane ring that has proven extremely useful to optimize the pharmacological profile of 
bioactive peptides. Particularly notable has been the use of (S,S,S)-Oic for the design of 
angiotensin-converting enzyme (ACE) inhibitors,
9
 antagonists for the B2 receptor of 
 4 
bradykinin
10,11 
and prolyl oligopeptidase (POP) inhibitors.
12
 Such (S,S,S)-Oic-containing 
compounds are useful, among other applications, as antihypertensive drugs, anti-inflammatory 
agents, for the prevention of heart failure, or the treatment of neurodegenerative diseases and, in 
fact, a number of them are already on the market or have entered clinical evaluation.
 
As the -methylated counterpart of Oic, -methyloctahydroindole-2-carboxylic acid [( Me)Oic, 
Fig. 1)] is of high intrinsic value as a potential modulator of the conformational constraints 
induced by proline. Both Oic and ( Me)Oic bear an additional cyclohexane ring with reference to 
the parent amino acid, proline. This structural feature is appropriate to build up hydrophobic 
recognition interactions at the binding site of receptors and to endow peptides with greater 
lipophilicity, which, in turn, may translate into enhanced affinity and bioavailability. Moreover, 
the stereochemical diversity of Oic and ( Me)Oic greatly increases their potential for the design 
of peptides. It should be noted that, for a given configuration at the  carbon, four different 
dispositions of the fused cyclohexane ring are possible. The variety of shapes provided by the 
different Oic and ( Me)Oic stereoisomers may be of help to fine-tune the interaction with the 
hydrophobic pocket of a receptor and to elucidate the bioactive conformations of peptides. 
In spite of its great potential value, the behavior of ( Me)Oic when included into peptides or 
other biologically relevant systems remains unexplored. This is due to the lack of synthetic 
methodologies providing access to the different stereoisomers of ( Me)Oic in enantiomerically 
pure form. In fact, at variance with Oic, attention on the -methylated counterpart ( Me)Oic has 
been focused only recently. Within this context, we have described the preparation of enantiopure 
(S,S,S)-( Me)Oic
13
 and its epimer at the  carbon (R,S,S)-( Me)Oic
14 
by means of 
stereoselective alkylation processes. To the best of our knowledge, these are, together with the 
preparation of (S,S,S)-( Me)Oic described in a patent,
15
 the only synthetic routes to ( Me)Oic 
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reported to date. Therefore, development of efficient methodologies that ensure accessibility to 
these and other ( Me)Oic stereoisomers, in optically pure form and significant quantities, 
remains a challenge. We describe here a convenient route for the multigram-scale preparation of 
both (S,S,S)-( Me)Oic and (R,R,R)-( Me)Oic in enantiomerically pure form. The procedure 
combines the synthesis of a racemic precursor and a chromatographic resolution procedure. 
MATERIALS AND METHODS 
General 
All reagents from commercial suppliers were used without further purification. Thin-layer 
chromatography (TLC) was performed on Macherey-Nagel Polygram syl G/UV precoated silica 
gel polyester plates. The products were visualized by exposure to UV light (254 nm), iodine 
vapour or submersion in cerium molybdate stain [aqueous solution of phosphomolybdic acid 
(2%), CeSO4·4H2O (1%) and H2SO4 (6%)]. Column chromatography was performed using 
Macherey-Nagel 60Å silica gel. Melting points were determined on a Gallenkamp apparatus and 
are uncorrected. IR spectra were registered on a Mattson Genesis or a Nicolet Avatar 360 FTIR 
spectrophotometer; max is given for the main absorption bands. 
1
H and 
13
C NMR spectra were 
recorded on a Bruker AV-400 instrument at room temperature using the residual solvent signal as 
the internal standard; chemical shifts ( ) are expressed in ppm and coupling constants (J) in 
Hertz. Optical rotations were measured at room temperature using a JASCO P-1020 polarimeter. 
High-resolution mass spectra were obtained on a Bruker Microtof-Q spectrometer. 
High-Performance Liquid Chromatography 
HPLC was carried out using a Waters 600 HPLC system equipped with a 2996 photodiode array 
detector and a 2487 dual wavelength absorbance detector (respectively used for monitoring 
analytical and preparative separations). The solvents used as mobile phases were of spectroscopic 
 6 
grade. Analytical assays were performed on Chiralpak
®
 IA, IB, and IC columns (Daicel Chemical 
Industries Ltd., Japan) of 250  4.6 mm ID using different binary and ternary mixtures as eluents 
and working at flow rates ranging from 0.7 to 1.0 ml/min. The preparative resolution was carried 
out on a 250  20 mm ID Chiralpak
®
 IC column eluting with n-hexane/tert-butyl methyl ether/2-
propanol 50/44/6 (see below for further details). Both the column loading capacity (i.e. the 
maximum sample mass that the column can hold) and the optimum sample concentration had 
previously been determined on the analytical 250  4.6 mm ID Chiralpak
®
 IC column by 
injecting increasing amounts of sample at different concentrations. The capacity (k ), selectivity 
( ) and resolution (RS) factors are defined as follows: k  = (tr – t0)/t0,  = k 2/k 1, RS = 1.18 (t2 – 
t1)/(w2 + w1), where subscripts 1 and 2 refer to the first and second eluted enantiomers, tr (r = 1, 
2) are their retention times, and w1 and w2 denote their half-height peak widths; t0 is the dead 
time. 
X-ray diffraction 
Colorless single crystals of racemic (S*,S*,S*)-10 were obtained by slow evaporation from a 
dichloromethane/ethyl acetate solution. The X-ray diffraction data were collected at 100K on an 
Oxford Diffraction Xcalibur diffractometer provided with a Sapphire CCD detector, using 
graphite-monochromated Mo-K  radiation ( = 0.71073 Å). The structure was solved by direct 
methods using SHELXS-97
16
 and refinement was performed using SHELXL-97
17 by the full-
matrix least-squares technique with anisotropic thermal factors for heavy atoms. Hydrogen atoms 
were located by calculation and affected by an isotropic thermal factor fixed to 1.2 times the Ueq 
of the carrier atom (1.5 for the methyl protons). Crystallographic data (excluding structure 
factors) for the structure reported in this paper have been deposited with the Cambridge 
Crystallographic Data Centre as supplementary publication number CCDC 746151. Copies of the 
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data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 
1EZ, UK [fax: +44(0)-1223-336033 or e-mail: deposit@ccdc.cam.ac.uk]. 
Crystallographic data: orthorhombic, space group Pbca; a = 7.5997(2) Å, b = 17.0955(6) Å, c = 
18.1963(6) Å; Z = 8; dcalcd = 1.313 g.cm
–3
; 18156 reflections collected, 3133 unique (Rint = 
0.0401); data/parameters: 3133/137; final R indices (I > 2 I): R1 = 0.036, wR2 = 0.089; final R 
indices (all data): R1 = 0.062, wR2 = 0.102; highest residual electron density: 0.39 e Å
–3
. 
Syntheses 
Synthesis of methyl N-(tert-butoxycarbonyl)indole-2-carboxylate (9). To a solution of indole-
2-carboxylic acid (8) (4.0 g, 24.82 mmol) in methanol (135 ml), sulfuric acid (2.30 ml, 40.77 
mmol) was added dropwise. The reaction mixture was heated under reflux for 6 h. The solvent 
was evaporated and the residue was dissolved in dichloromethane (70 ml) and washed with 
saturated aqueous NaHCO3. The organic layer was dried over MgSO4 and filtered. After 
evaporation of the solvent, the remaining residue was dissolved in tetrahydrofuran (100 ml) and 
4-(dimethylamino)pyridine (361 mg, 2.93 mmol) and di-tert-butyl dicarbonate (6.40 g, 29.32 
mmol) were added. The reaction mixture was kept at room temperature for 2 h and then the 
solvent was evaporated. The resulting residue was dissolved in ethyl acetate (70 ml) and washed 
with saturated aqueous NaHCO3. The organic phase was dried over MgSO4 and filtered. The 
crude product obtained after evaporation of the solvent was purified by column chromatography 
(eluent: hexanes/ethyl acetate 10/1) to give pure 9 as a white solid (6.36 g, 23.10 mmol, 93% 
yield). Mp 68–70 ºC. IR (KBr)  3019, 2981, 1745, 1712, 1556 cm–1. 1H NMR (CDCl3, 400 
MHz)  1.78 (s, 9H), 4.08 (s, 3H), 7.26 (m, 1H), 7.42 (m, 1H), 7.57 (m, 1H), 7.76 (m, 1H), 8.25 
(m, 1H). 
13
C NMR (CDCl3, 100 MHz) 27.78, 52.28, 84.55, 114.82, 122.12, 123.25, 126.77, 
 8 
127.44, 130.34, 137.79, 149.20, 162.31. HRMS (ESI) C15H17NNaO4 [M+Na]
+
: calcd 298.1050, 
found 298.1039. 
Synthesis of methyl (2S*,3aS*,7aS*)-N-(tert-butoxycarbonyl)octahydroindole-2-carboxylate 
[(S*,S*,S*)-4]. A solution of 9 (6.0 g, 21.79 mmol) in acetic acid (80 ml) was hydrogenated at 
room temperature and atmospheric pressure in the presence of PtO2 (600 mg). After 24 h, the 
catalyst was filtered off and washed with acetic acid. The solvent was evaporated to dryness and 
the residue was dissolved in dichloromethane (70 ml) and washed with saturated aqueous 
NaHCO3. The organic layer was dried over MgSO4 and filtered. The solvent was evaporated and 
the residue purified by column chromatography (eluent: hexanes/ethyl acetate 10/1) to afford 
pure (S*,S*,S*)-4 as a colorless oil (5.87 g, 20.72 mmol, 95% yield). HRMS (ESI) C15H25NNaO4 
[M+Na]
+
: calcd 306.1676, found 306.1679. Spectroscopic data are identical to those reported 
previously
13
 for the (S,S,S) enantiomer. 
Synthesis of methyl (2S*,3aS*,7aS*)-N-(tert-butoxycarbonyl)-2-methyloctahydroindole-2-
carboxylate [(S*,S*,S*)-5]. A 1.8 M solution of LDA in hexanes (26.20 ml, 47.16 mmol) was 
added dropwise to a stirred solution of (S*,S*,S*)-4 (5.70 g, 20.11 mmol) in anhydrous 
tetrahydrofuran (105 ml) kept under an inert atmosphere, at –78 ºC. After stirring at this 
temperature for 30 min, methyl iodide (5.20 ml, 81.35 mmol) was added dropwise. The resulting 
solution was warmed to –50 ºC and kept at this temperature overnight. The reaction mixture was 
quenched with saturated aqueous NH4Cl (20 ml) and extracted with dichloromethane several 
times. The organic phase was dried over anhydrous MgSO4 and filtered. The solvent was 
eliminated and the residue was purified by column chromatography (eluent: hexanes/ethyl acetate 
10/1) to afford pure (S*,S*,S*)-5 as a colorless oil (4.48 g, 15.06 mmol, 75% yield). IR (neat)  
1743, 1693 cm
–1
. 
1
H NMR (DMSO-d6, 400 MHz)  1.06 (m, 1H), 1.14–1.50 (m, 3H) overlapped 
with 1.30, 1.36 (two s, 9H) and with 1.43, 1.45 (two s, 3H), 1.54–1.68 (m, 4H), 1.94–2.10 (m, 
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1H), 2.11–2.25 (m, 1H), 2.40–2.48 (m, 1H), 3.60–3.72 (m, 1H) overlapped with 3.60, 3.65 (two 
s, 3H). 
13
C NMR (DMSO-d6, 100 MHz)  (duplicate signals are observed for most carbons) 
20.10, 20.21; 21.77, 23.13; 23.00, 23.23; 25.03, 25.11; 25.65, 26.46; 27.85, 28.01; 33.62, 34.54; 
38.87, 39.97; 51.86, 52.04; 57.52, 57.68; 64.40; 78.41, 78.52; 151.66, 152.32; 174.37, 174.66. 
HRMS (ESI) C16H27NNaO4 [M+Na]
+
: calcd 320.1832, found 320.1835. 
Synthesis of methyl (2S*,3aS*,7aS*)-2-methyloctahydroindole-2-carboxylate hydrochloride 
[(S*,S*,S*)-10]. A 3N solution of hydrogen chloride in anhydrous ethyl acetate (20 ml) was 
added to (S*,S*,S*)-5 (4.40 g, 14.80 mmol) and the reaction mixture was stirred at room 
temperature for 4 h. The solvent was eliminated and the solid was dissolved in water and 
lyophilized to afford (S*,S*,S*)-10 (3.46 g, 14.80 mmol, 100% yield). Mp 167–169 ºC. HRMS 
(ESI) C11H20NO2 [M–Cl]
+
: calcd 198.1489, found 198.1485. Spectroscopic data are identical to 
those reported in our previous work
13
 for the (S,S,S) enantiomer. 
Synthesis of methyl (2S*,3aS*,7aS*)-N-(benzyloxycarbonyl)-2-methyloctahydroindole-2-
carboxylate [(S*,S*,S*)-11]. To an ice-cooled solution of (S*,S*,S*)-10 (3.42 g, 14.63 mmol) 
and N,N-diisopropylethylamine (10.4 ml, 59.68 mmol) in dry dichloromethane (75 ml), benzyl 
chloroformate (4.40 ml, 29.28 mmol) was added dropwise. Once the addition was completed, the 
reaction was kept at room temperature overnight. The mixture was washed with saturated 
aqueous NaHCO3, and the organic phase was dried over anhydrous MgSO4 and filtered. The 
solvent was evaporated and the residue was purified by column chromatography (eluent: 
hexanes/ethyl acetate 10/1) to give (S*,S*,S*)-11 as a colorless oil (4.47 g, 13.49 mmol, 92% 
yield). IR (neat)  3035, 2950, 1743, 1702 cm
–1
. 
1
H NMR (DMSO-d6, 400 MHz)  1.00–1.28 (m, 
2H), 1.34–1.73 (m, 6H) overlapped with 1.46 and 1.48 (two s, 3H), 1.94, 2.08 (two m, 1H), 2.16–
2.27 (m, 1H), 2.44–2.56 (m, 1H), 3.48, 3.62 (two s, 3H), 3.79 (m, 1H), 4.94–5.11 (m, 2H), 7.25–
7.45 (m, 5H) 
13
C NMR (DMSO-d6, 100 MHz) duplicate signals are observed for most carbons) 
 10 
19,98, 20.12; 21.63; 22.97, 23.07; 24.89, 24.97; 25.60, 26.61; 33.61, 34.53; 38.80, 40.23; 52.11; 
57.66, 58,23; 64.53, 64.96; 65.55, 65.85; 127.21; 127.42; 127.64, 127.69; 128.23; 128.30; 
136.49, 136.93; 152.48, 152.80; 174.09, 174.35. HRMS (ESI) C19H25NNaO4 [M+Na]
+
: calcd 
354.1676, found 354.1676. 
Resolution of (S*,S*,S*)-11: isolation of methyl (2S,3aS,7aS)- and (2R,3aR,7aR)-N-
(benzyloxycarbonyl)-2-methyloctahydroindole-2-carboxylate [(S,S,S)-11 and (R,R,R)-11]. 
HPLC resolution of racemic (S*,S*,S*)-11 (4.142 g) dissolved in chloroform (6.90 ml) was 
carried out by successive injections (one every 11.5 min) of 600 l on a 250  20 mm ID 
Chiralpak
®
 IC column. A mixture of n-hexane/tert-butyl methyl ether/2-propanol 50/44/6 was 
used as the eluent working at a flow rate of 16 ml/min and with UV monitoring at 220 nm. Three 
separate fractions were collected. Optically pure (S,S,S)-11 (2.043 g) and (R,R,R)-11 (2.006 g) 
were respectively obtained by evaporation of the first and third fractions. The second fraction 
contained 38 mg of a 22/78 mixture of (S,S,S)-11/(R,R,R)-11 and was discarded. 
(S,S,S)-11: colorless oil. [ ]D –9.6 (c 0.92, CHCl3). 
(R,R,R)-11: colorless oil. [ ]D +9.5 (c 0.95, CHCl3). 
Spectroscopic data for (S,S,S)- and (R,R,R)-11 are identical to those given above for the racemic 
compound. 
Synthesis of (2S,3aS,7aS)-N-(benzyloxycarbonyl)-2-methyloctahydroindole-2-carboxylic 
acid [(S,S,S)-12]. A 1M solution of potassium hydroxide in methanol (50 ml) was added to 
(S,S,S)-11 (2.04 g, 6.16 mmol) and the reaction mixture was heated under reflux for 24 h. After 
evaporation of the solvent, the residue was taken up in water and washed with diethyl ether. The 
aqueous phase was acidified with 5% aqueous KHSO4 and extracted with ethyl acetate (3 x 50 
ml). The combined organic layers were dried over anhydrous MgSO4 and filtered. Evaporation of 
   
11 
 
the solvent gave (S,S,S)-12 as a white foam (1.94 g, 6.11 mmol, 99% yield). [ ]D +11.8 (c 0.81, 
MeOH). IR (KBr)  3500–2480, 3064, 2931, 1743, 1697 cm–1. 1H NMR (CDCl3, 400 MHz)  
1.03–1.35 (m, 2H), 1.44–1.78 (m, 6H) overlapped with 1.53, 1.62 (two s, 3H), 2.05, 2.26 (two m, 
1H), 2.40–2.55 (m, 2H), 3.88, 3.95 (two m, 1H), 5.05–5.14 (m, 2H), 7.22–7.38 (m, 5H), 9.48 (bs, 
1H). 
13
C NMR (CDCl3, 100 MHz)  (duplicate signals are observed for most carbons) 20.37, 
20.59; 21.98, 23.05; 23.49, 23.65; 25.53, 25.60; 26.00, 27.05; 34.46, 34.98; 39.63, 41.24; 58.61, 
58.98; 64.95, 65.74; 66.89, 66.94; 127.66, 127.70; 127.77; 127.88; 128.29; 128.42; 136.41, 
136.58; 153.49, 154.51; 179.24, 180.82. HRMS (ESI neg.) C18H22NO4 [M–H]
–
: calcd 316.1554, 
found 316.1554. 
Synthesis of (2R,3aR,7aR)-N-(benzyloxycarbonyl)-2-methyloctahydroindole-2-carboxylic 
acid [(R,R,R)-12]. An identical procedure to that described above was applied to transform 
(R,R,R)-11 (2.01 g, 6.06 mmol) into (R,R,R)-12 (1.91 g, 6.03 mmol, 99% yield). [ ]D –12.0 (c 
0.85, MeOH). HRMS (ESI neg.) C18H22NO4 [M–H]
–
: calcd 316.1554, found 316.1558. 
Spectroscopic data are the same as those described for (S,S,S)-12. 
RESULTS AND DISCUSSION 
Synthesis of a racemic precursor 
The first stage in the synthesis of enantiomerically pure (S,S,S)- and (R,R,R)-( Me)Oic involved 
the preparation of a racemic common precursor to be subsequently subjected to HPLC resolution. 
The synthesis of such a precursor was addressed by modification of the asymmetric route 
previously reported
13
 for the preparation of enantiopure (S,S,S)-( Me)Oic, which is presented in 
Fig. 2. It began with the hydrogenation of commercially available (S)-indoline-2-carboxylic acid, 
(S)-1, using PtO2 as a catalyst to afford a 90:10 mixture of the (S,S,S) and (S,R,R) 
 12 
octahydroindole derivatives. The two epimeric compounds retain the (S) configuration at the  
carbon present in the starting material and differ in the stereochemistry of the two new chiral 
centers formed. The desired (S,S,S) stereoisomer was isolated pure by recrystallization and was 
protected at the carboxylic acid and amino functionalities to give (S,S,S)-4. This N-Boc amino 
ester underwent a stereoselective -methylation reaction and the major diastereoisomer, (S,S,S)-
5, was isolated by column chromatography. Subsequent deprotection of the carboxylic acid 
yielded (S,S,S)-( Me)Oic in the N-Boc protected form, that is, adequately protected for use in 
peptide chemistry. 
<Figure 2> 
The racemic version of this methodology would require the use of racemic indoline-2-carboxylic 
acid (rac-1) as a substrate (Fig. 3). Alternatively, the completely unsaturated compound, indole-
2-carboxylic acid (8) (Fig. 3), can be envisaged as a less expensive starting material for the 
preparation of the racemate (S*,S*,S*)-4. However, according to the literature,
18,19
 the catalytic 
hydrogenation of the indole system requires harsh reaction conditions (high temperatures and 
pressures of hydrogen gas). Yet, some ester derivatives of 8 have been reported
20
 to undergo 
hydrogenation under Rh/C catalysis and hydrogen pressure at room temperature.
  
<Figure 3> 
Based on this precedent, we undertook the preparation of the target amino acids, (S,S,S)- and 
(R,R,R)-( Me)Oic, starting from an adequately protected derivative of indole-2-carboxylic acid 
(8), namely the N-Boc protected ester 9 (Fig. 3). The latter compound was readily obtained by 
reaction of 8 with methanol in the presence of sulfuric acid followed by treatment with di-tert-
butyl dicarbonate. The hydrogenation of 9 using PtO2 as a catalyst was accomplished at room 
temperature and atmospheric pressure of hydrogen gas. It seems, therefore, that both the amino 
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and carboxylic acid functions in 8 are to be in the protected form (as are in 9) for the 
hydrogenation of the indole system to proceed under such mild conditions. The choice of PtO2 as 
the catalyst for this reaction was based on our previous observation
13
 that the aromatic ring in (S)-
1 is efficiently hydrogenated at atmospheric pressure in the presence of PtO2 (Fig. 2), whereas the 
use of Pd/C or Rh requires high pressure of hydrogen.
21,22
 Moreover, we were delighted to 
observe that the hydrogenation of 9 provided racemic (S*,S*,S*)-4 as a single product. This 
differential behavior with respect to that described above for (S)-1 (Fig. 2) is due to the fact the 
three chiral centers are formed at once upon hydrogenation of 9 (Fig. 3). Accordingly, only the 
compound exhibiting a cis relative disposition of the two bridgehead hydrogen atoms and that at 
the  position, (S*,S*,S*)-4, is obtained in this process.  
Therefore, the route in Fig. 3 constitutes a highly efficient manner to access racemic (S*,S*,S*)-4 
as a single stereoisomer in high overall yield (88%) starting from inexpensive indole-2-carboxylic 
acid (8). Certainly, this route is much more convenient for the production of racemic Oic 
derivatives exhibiting an (S*,S*,S*) relative stereochemistry than the racemic version of the 
asymmetric synthesis reported before
13
 (Fig. 2), that would require the use of indoline-2-
carboxylic acid (rac-1) as a substrate. As outlined above, the procedure in Fig. 3 is more 
advantageous in terms of accessibility of the starting material (8 is substantially cheaper than rac-
1), global yield, hydrogenation conditions (the process in Fig. 2 requires heating at 60 ºC), and 
stereoselectivity of the hydrogenation process (complete vs 90:10). The synthetic pathway in Fig. 
3 is therefore highly convenient for the production of (S*,S*,S*)-Oic derivatives on a large scale. 
Once racemic (S*,S*,S*)-4 was obtained according to the procedure in Fig. 3, the synthetic route 
proceeded in a similar way to that described in the asymmetric version previously reported
13
 and 
shown in Fig. 2. Thus, the treatment of (S*,S*,S*)-4 with lithium diisopropylamide generated an 
intermediate lithium enolate that reacted with methyl iodide to provide an 89:11 mixture of the 
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two possible diastereoisomers, (S*,S*,S*)-5 and (R*,S*,S*)-6 (Fig. 4). It should be noted that the 
high steric hindrance imposed by the cis-fused cyclohexane ring was responsible for the efficient 
facial stereodifferentiation observed.
13 
The major diastereoisomer, (S*,S*,S*)-5, was isolated pure 
from the crude mixture by column chromatography in 75% yield. 
<Figure 4> 
At this stage, we undertook the exchange of the N-Boc protecting group by the Cbz one, as the 
latter has the advantage of absorbing in the UV range, thus favoring monitoring of the subsequent 
chromatographic resolution process. This was achieved by treatment of (S*,S*,S*)-5 with a 
saturated solution of hydrogen chloride in ethyl acetate followed by reaction with benzyl 
chloroformate (Fig. 4). In this way, several grams of (S*,S*,S*)-11 were prepared in 61% overall 
yield from indole-2-carboxylic acid (8). The intermediate amino ester hydrochloride, (S*,S*,S*)-
10, furnished single crystals suitable for X-ray diffraction analysis. The crystalline structure (Fig. 
5) confirmed the expected (S*,S*,S*) relative stereochemistry. As shown in Fig. 5, the 
cyclohexane ring adopts a chair conformation, which is slightly distorted to accommodate the cis-
fused five-membered cycle. The latter exhibits an envelope shape, with one of the carbon atoms 
involved in the fusion (3a) occupying the flap of the envelope. It should be noted that inversion of 
the reactions sequence carried out to transform (S*,S*,S*)-4 into (S*,S*,S*)-11 was examined, 
but only poor results were obtained. Thus, when the Cbz group was introduced in (S*,S*,S*)-4 
prior to the -methylation reaction, the latter process afforded only a 25% yield of (S*,S*,S*)-11 
(Fig. 4). Accordingly, this alternative pathway was discarded.
 
<Figure 5> 
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HPLC resolution: Isolation of enantiopure amino acids 
Once the racemic precursor of the target amino acids, (S*,S*,S*)-11, had been obtained, we 
addressed its resolution by HPLC. The separation of enantiomers by preparative chromatography 
using chiral stationary phases is nowadays recognized as a powerful tool to produce enantiopure 
compounds.
23–25
 Polysaccharide-based stationary phases are particularly suitable for this purpose 
due to their excellent chiral recognition ability and high loading capacity.
23–25
 Moreover, HPLC 
columns containing immobilized cellulose and amylose derivatives have recently become 
commercially available (Chiralpak
®
 IA, IB, and IC).
26–28
 In these columns, the chiral support is 
covalently bonded to the silica matrix, which results in a high stability in the presence of all 
organic solvents.
25–29
 This feature means a great advantage for resolutions on a preparative scale. 
Chiral stationary phases of this type, either commercial or made at the laboratory (prior to their 
commercialization), have been used in our group for the preparative HPLC resolution of a wide 
variety of non-natural protected amino acids.
30–41 
The resolution of racemic (S*,S*,S*)-11 was firstly tested at the analytical level using 250  4.6 
mm Chiralpak
®
 IA, IB, and IC columns, that respectively contain tris(3,5-
dimethylphenylcarbamate) of amylose,
26
 tris(3,5-dimethylphenylcarbamate) of cellulose,
27
 and 
tris(3,5-dichlorophenylcarbamate) of cellulose as the chiral selector.
28
 The screening started using 
mixtures of n-hexane/2-propanol as the eluent. The enantiomers of 11 could not be distinguished 
on the IA column, whereas both Chiralpak
®
 IB and IC showed excellent enantiodiscrimination 
abilities, with selectivity factors around 1.6 (Table 1). Replacement of the alcohol component in 
the eluting mixture by acetone was next tested. This change had little effect for the cellulose-
based phases, whereas very much improved the chiral recognition ability of Chiralpak
®
 IA. In 
fact, an almost complete baseline separation of peaks was achieved when eluting with n-
hexane/acetone 96/4 (v/v) on this stationary phase (Table 1). In spite of this, it remained much 
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less effective that the cellulose-derived ones and was therefore not considered for further assays. 
The addition of a third component to the initial n-hexane/2-propanol mixture was then evaluated. 
Among those tested, tert-butyl methyl ether provided the best results, particularly for the IC 
column (Table 1). Thus, when working on this stationary phase, the presence of a high percentage 
of this solvent in the mobile phase not only improved the selectivity but also led to a substantial 
enhancement of the resolution factor. Moreover, this change also resulted beneficial to the sample 
solubility, which is an extremely important issue for the subsequent scaling-up stage. 
Accordingly, the analytical conditions considered to be optimal for extension to the preparative-
scale enantioseparation were elution with a 50/44/6 (v/v/v) mixture of n-hexane/tert-butyl methyl 
ether/2-propanol at a flow rate of 0.8 ml/min on Chiralpak
®
 IC. The profile obtained under such 
chromatographic conditions is shown in Fig. 6. Further assays carried out on the IC analytical 
column working in an overload mode confirmed that these eluting conditions provided the 
optimal results in terms of both resolution and column loadability. 
<Table 1> 
<Figure 6> 
These conditions were subsequently scaled-up for the preparative resolution of (S*,S*,S*)-11 on a 
250  20 mm ID Chiralpak
®
 IC column. Successive injections of 600 l of a highly concentrated 
solution of the sample in chloroform (600 mg per ml of solvent) were performed (Fig. 7). Each 
run was collected into three separate fractions according to the cut points indicated in Fig. 7, with 
equivalent fractions of successive injections being combined. Following this protocol, a total of 
4.14 g of racemate were submitted to the resolution procedure, which was completed in about 3 
h. Evaporation of the first and third fractions provided 2.04 and 2.01 g of the first and second 
eluted enantiomers, respectively, both of them in optically pure form, as assessed at the analytical 
level (Fig. 8). This means that 98% of the injected material was recovered in enantiomerically 
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pure form after a single passage through the column. The high productivity of the 
enantioseparation process is therefore remarkable since more than 1 g of optically pure material 
was isolated per hour working on a semi-preparative size column. 
< Figure 7> 
<Figure 8> 
The absolute configuration of the isolated enantiomers was assigned by comparison of their 
retention times with that of a sample of enantiomerically pure (S,S,S)-11 prepared separately. 
Thus, a small amount of (S,S,S)-5 obtained from (S)-indoline-2-carboxylic acid in our previous 
work
13
 following the synthetic procedure in Fig. 2 was transformed into (S,S,S)-11 by exchange 
of the Boc-Cbz N-protecting groups, and its retention time was found to be coincident with that 
of the first eluted enantiomer of 11 (Fig. 8). Accordingly, the more strongly retained enantiomer 
of 11 was assigned an (R,R,R) configuration. 
Finally, each enantiomer of 11 was subjected to saponification to provide the corresponding N-
Cbz amino acid in almost quantitative yield (Fig. 9). Thus, the target compounds, (S,S,S)- and 
(R,R,R)-( Me)Oic, were isolated in enantiomerically pure form and suitably protected for further 
derivatization, including their direct use in peptide synthesis. The Cbz protecting group can be 
eliminated to liberate the amino function under mild reaction conditions that do not affect the 
optical integrity of the compounds. 
<Figure 9> 
CONCLUSION 
We have developed an efficient and practical method for the production of multigram quantities 
of the -tetrasubstituted proline analogues (S,S,S)- and (R,R,R)- -methyloctahydroindole-2-
 18 
carboxylic acids in enantiomerically pure form and suitably protected for incorporation into 
peptides. The procedure relies in the use of inexpensive indole-2-carboxylic acid as the starting 
material, which allows the preparation of a racemic precursor in high overall yield through simple 
transformations, and the efficiency of the HPLC resolution process carried out on a chiral column 
(Chiralpak
®
 IC). The procedure has been applied to the isolation of significant quantities of 
optically pure compounds and can be easily scaled-up to the production of larger amounts. The 
amino acids thus prepared are proline analogues of great value in the design of peptides with 
pharmacological applications and other medicinally relevant compounds. 
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FIGURE CAPTIONS 
Figure 1. Structure of different proline analogues: -methylproline [( Me)Pro], 
octahydroindole-2-carboxylic acid (Oic), and 2-methyloctahydroindole-2-carboxylic acid 
[( Me)Oic]. Chiral carbons in the octahydroindole system (corresponding to positions 2, 3a, and 
7a) are indicated with asterisks. All throughout the text, a nomenclature without numerical 
locants will be used for the sake of simplicity; accordingly, a (2S,3aS,7aS) stereochemistry will 
be denoted as (S,S,S). 
Figure 2. Stereoselective synthesis for enantiopure (S,S,S)-( Me)Oic previously reported (ref. 
13). Abbreviations: Boc, tert-butoxycarbonyl; LDA, lithium diisopropylamide. 
Figure 3. Synthesis of racemic (S*,S*,S*)-4.  
Figure 4. Synthesis of the racemic precursor of the target amino acids, (S*,S*,S*)-11. 
Abbreviations: Cbz, benzyloxycarbonyl. 
Figure 5. X-ray crystal structure of racemic (S*,S*,S*)-10 [only the (S,S,S) enantiomer is shown]. 
Heteroatoms are drawn as thermal ellipsoids. Most hydrogens have been omitted for clarity.  
Figure 6. HPLC resolution of (S*,S*,S*)-11 at the analytical level. Column: Chiralpak
®
 IC (250 
 4.6 mm ID). Eluent: n-hexane/tert-butyl methyl ether/2-propanol 50/44/6. Flow rate: 0.8 
ml/min. UV detection: 210 nm. 
Figure 7. Preparative HPLC resolution of (S*,S*,S*)-11. Profile corresponding to the injection of 
600 l of a solution of 11 in chloroform (concentration: 600 mg solute / ml of solvent). The cut 
points for the three fractions collected are indicated. Column: Chiralpak
®
 IC (250  20 mm ID). 
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Eluent: n-hexane/tert-butyl methyl ether/2-propanol 50/44/6. Flow rate: 16 ml/min. UV detection: 
220 nm. 
Figure 8. HPLC analytical profile of the resolved enantiomers of 11. Chromatographic 
conditions as in Fig. 6.  
Figure 9. Preparation of N-protected enantiomerically pure (S,S,S)- and (R,R,R)-( Me)Oic. 
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Table 1. Selected chromatographic data for the analytical HPLC resolution of compound 
(S*,S*,S*)-11 on Chiralpak
®
 IA, IB, and IC columns
a
 
  
eluent
b
 % (v/v) k'1  RS  
  
Chiralpak
®
 IA 
n-Hx/2-propanol 98/2 2.4 1.0 –  
n-Hx/acetone
c
 96/4 2.4 1.1 1.3 
Chiralpak
®
 IB 
n-Hx/2-propanol 98/2 1.6 1.6 5.4 
n-Hx/acetone
c
 96/4 2.1 1.5 5.8 
n-Hx/t-BuOMe/2-propanol 80/19/1 1.6 1.6 5.6 
Chiralpak
®
 IC 
n-Hx/2-propanol 80/20 1.7 1.6 5.2 
n-Hx/acetone
c
 90/10
d
 1.0 1.5 5.3 
n-Hx/t-BuOMe/2-propanol 50/44/6
d
 1.3 1.9 6.7 
  
a
Column size: 250  4.6 mm ID. Flow rate: 1.0 ml/min (unless otherwise indicated). UV 
detection at 210 nm (unless otherwise indicated). The chromatographic parameters k'1, , and RS 
are defined in the Materials and Methods section. 
b
n-Hx: n-hexane; t-BuOMe: tert-butyl methyl ether. 
c
UV detection at 220 nm.  
d
Flow rate: 0.8 ml/min.  
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